🇺🇸 FDA
Patent

US 11149273

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

granted A61KA61K31/713A61P

Quick answer

US patent 11149273 (Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/713, A61P, A61P1/00, A61P1/04